La chaîne d'options affiche les données clés des options sur actions de Relmada Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Relmada Therapeutics..

Relmada Therapeutics (NASDAQ:RLMD) Stock, Chaîne d'Options

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

News

Press Releases

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

General

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Earnings

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Management

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

RLMD

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Gelteq

Hoth Therapeutics

IGC Pharma

Incannex Healthcare

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

PolyPid

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

SCYNEXIS

SenesTech

TherapeuticsMD

Mizuho

Leerink Partners

Jefferies

Goldman Sachs

RELMADA THERAPEUTICS by Relmada Therapeutics, Inc.

Comments

Relmada Therapeutics

Relmada Therapeutics (RLMD) Options

Relmada Therapeutics (NASDAQ:RLMD) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL